Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом *
Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом *
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Bertel O, Marx B, Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med 1987; 82–29.
2. Meyer JS, Rogers RL, Mortel RF. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16 (6): 985–90.
3. Hares P, James IM, Griffith D. Effect of acebutolol on cerebral circulation of a man. Br J Clin Pharmacol 1977; 4: 373–5.
4. Fuijshima M, Ibayashi S, Fugii K et al Effects of long-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17–5.
5. Fogari R, Zoppi A, Corradi L et al. b-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 534–9.
6. Vulpis V, Antonacci A, Prandi P et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189–93.
7. Верещагин Н.В.,Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–9.
9. Frithz G. Influense on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229–30.
10. Fogari R et al. b-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (suppl 5): S76.
11. Chang PC, van Veen S, Vermeij P, van Brummelen P. Double-blind compason of the b1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S58–60.
12. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61–4.
13. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
14. Haneda T, Ido A, Fijikane T et al. Effect of bisoprolol, a b1-selective b-blocer, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jpn J Geriat 1998; 35: 33–8.
15. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influece of bisiprolol on blood glucose, glucosuria and haemoglobin A1, in non-insulin-dependent diabetics. J Cardivasc Pharmacol 1986; 8 (suppl 11): s 96–9.
16. Dominguez LJ, Barbagallo M, Jacober SJ et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997; 10: 1349–55.
2. Meyer JS, Rogers RL, Mortel RF. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16 (6): 985–90.
3. Hares P, James IM, Griffith D. Effect of acebutolol on cerebral circulation of a man. Br J Clin Pharmacol 1977; 4: 373–5.
4. Fuijshima M, Ibayashi S, Fugii K et al Effects of long-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17–5.
5. Fogari R, Zoppi A, Corradi L et al. b-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 534–9.
6. Vulpis V, Antonacci A, Prandi P et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189–93.
7. Верещагин Н.В.,Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–9.
9. Frithz G. Influense on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229–30.
10. Fogari R et al. b-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (suppl 5): S76.
11. Chang PC, van Veen S, Vermeij P, van Brummelen P. Double-blind compason of the b1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S58–60.
12. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61–4.
13. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
14. Haneda T, Ido A, Fijikane T et al. Effect of bisoprolol, a b1-selective b-blocer, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jpn J Geriat 1998; 35: 33–8.
15. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influece of bisiprolol on blood glucose, glucosuria and haemoglobin A1, in non-insulin-dependent diabetics. J Cardivasc Pharmacol 1986; 8 (suppl 11): s 96–9.
16. Dominguez LJ, Barbagallo M, Jacober SJ et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997; 10: 1349–55.
Авторы
В.Б.Мычка, В.Б.Сергиенко, В.В.Горностаев, И.М.Двоскина, И.Е.Чазова
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.